Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • HIMS Q2FY25 revenue rose 72.6% YoY to USD 544.8m, driven by subscriber and ARPU growth.
  • HIMS Q2 net profit was USD 43.5m, up from USD 13.3m in Q2FY24.
  • HIMS ended Q2FY25 with USD 1,124.6m in cash, up 409.8% YoY.

Hims & Hers Health, Inc. (NYSE: HIMS) operates a digital health platform offering access to providers, electronic records, prescriptions, pharmacy services, and personalized care.

For the second quarter of FY25 (Q2FY25), the company reported total revenue of USD 544.8 million, up 72.6% from USD 315.7 million in Q2FY24, driven by a 31% increase in subscribers to over 2.4 million and a 30% rise in monthly online revenue per average subscriber to USD 74. Net profit was USD 43.5 million compared to USD 13.3 million a year earlier, reflecting higher revenue partly offset by increased cost of revenue and operating expenses. Cash from operating activities rose 13.3% to USD 90.0 million from USD 79.4 million, supported by higher net income and non-cash expenses, though partly offset by an unfavorable change in working capital. Cash and cash equivalents stood at USD 1,124.6 million at the end of Q2FY25, up 409.8% from USD 220.6 million, due to inflows from operating and financing activities, partly offset by investing outflows.

Business Update
On  July 09 2025, the company announced plans to expand into Canada in 2026 with its holistic weight loss program, coinciding with the anticipated first-ever global availability of generic semaglutide. The expansion follows the completion of the acquisition of ZAVA, a European digital health platform.

Company Outlook
Hims & Hers Health, Inc. projects Q3 2025 revenue of USD 570–590 million with Adjusted EBITDA of USD 60–70 million, representing an Adjusted EBITDA margin of 11–12%. For full-year 2025, the company expects revenue between USD 2.3 billion and USD 2.4 billion and Adjusted EBITDA in the range of USD 295–335 million, corresponding to a margin of 13–14%.

Top 10 Shareholders

The top 10 shareholders collectively account for around 56.23% of the company’s total shareholding, indicating a concentrated ownership structure. BlackRock Institutional Trust Company, N.A., and The Vanguard Group, Inc. hold the largest stakes, at 9.96% and 9.38%, respectively.


Stock Information 

Hims & Hers Health closed at USD 44.57 on August 22, 2025, up 1.39% intraday. Over the past month, the stock has dropped 23.18%, while its three-month and six-month returns stand at -18.71% and -9.56%, respectively. Despite recent weakness, HIMS has delivered a year-to-date gain of 84.33% and surged 170.78% over the past year. The stock trades 38.93% below its 52-week high of USD 72.98 (February 19, 2025) but remains significantly above its 52-week low of USD 13.47 (September 6, 2024).

Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference data for all price data, currency, technical indicators, support, and resistance levels Is 22 August 2025. The reference data in this report has been partly sourced from EODHD/Others.  

Technical Indicators Defined

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.